






Validation of the French version of a quality of life instrument designed for teenagers with cancer GEURTEN C., MD, HOYOUX C., MD, PIETTE C., MD, GEURTEN M., PhD

Background: Amendments of therapy protocols for childhood malignancies have led to improvement of survival rates, shifting the focus of further researches from optimization of outcome to assessment and prevention of late toxicities due to treatment.
Quality of life (QoL) during and after completion of therapy is a good indicator of disadvantages and benefits of treatment. Assessment of this parameter is thus indispensable to a comprehensive evaluation of late effects. 
There are numerous existing QoL scales, with only a few ones specifically designed for childhood cancer survivors. Yet, French-language tools are scarce. Moreover, quality of life among teenagers requires specific assessment, since the importance of the different aspects of life at adolescence differs from adulthood.
Aim: The present study was led to validate in its French-form the quality of life instrument entitled Manchester Minneapolis Quality of Life Tool - Adolescent Form (MMQL - AF), a tool designed in 2002 by S. Batia and al. in order to study self-reported QoL through 7 subscales (physical, social, psychological and cognitive functioning, intimate relationships, body development and global outcome) in teenagers suffering and having suffered from childhood malignancies.
Material and Methods: The original questionnaire was translated in French and proofread by two independent native English speakers and then submitted to 138 teenagers aged 10 to 20, i.e. 30 teenagers in treatment for cancer, 30 teenagers off treatment for such disease and 78 healthy controls. All patients had to concomitantly fill the well-known generalist SF-36 QoL tool to study concordant validity and 30 controls were submitted the MMQL 6 weeks later to assess test-retest reliability.
Results: Patients and controls were similar for sex, age and parental educational level. Similarly to the original scale, the French version of MMQL-AF demonstrated good intern reliability for the whole scale (α-Cronbach = .91), and for each subscale (from .70 to .86). The tool was able to discriminate between patients and controls (F(1,96) = 6.53, p =.01), but not between patients on and off treatment (F(1,96)=0.88, p =.34), except for the physical (F(1,94) = 7.97, p =.005) and cognitive (F(1,94) = 3.72, p =.05) functioning, where patients on treatment scored significantly lower than patients having ended therapy. The concordant validity between MMQL-AF and SF-36 was significant (r = .70, p < .001).  Test-Retest fidelity of the questionnaire was more than satisfactory (r = .81, p < .001).
Conclusion: The French version of MMQL-AF is herein proven to be a valuable tool to assess QoL in teenagers. The data collected show that the impact of the malignancy in these children is more pronounced on physical and cognitive ability. MMQL-AF can thus now be safely used in French-speaking cohorts, particularly in malignancy follow-up studies.









